A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor.
Aside from physiological tremor, essential tremor (ET) is by far the most common cause of tremor in humans, affecting large numbers of individuals in every human population. The crude prevalence of ET has been conservatively estimated to be between 0.4% and 3.9%, although some estimates of the prevalence of ET among the elderly are higher than 20%. Essential tremor is the most prevalent adult-onset movement disorder, and is also regarded as one of the most common neurological disorders of adults, with a prevalence that is similar to or greater than that of stroke, Alzheimer disease, migraine headache, and lumbosacral pain syndromes. Essential tremor is as much as 20 times more prevalent than Parkinson disease.
Louis
E D
ED
Department of Neurology and the Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists / Q000009:adverse effects*; D000077206:Gabapentin; D006801:Humans; D011324:Primidone / Q000009:adverse effects*; D011433:Propranolol / Q000009:adverse effects*; D014202:Tremor / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists; D011324:Primidone; C017985:progabide; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D011433:Propranolol